Evaluation of Post-Vaccination Symptoms of Two Common COVID-19 Vaccines Used in Abha, Aseer Region, Kingdom of Saudi Arabia

Figures & data

Table 1 Demographic Characteristics of the Participants and Clinical History

Variables	Frequency	Percent
Gender
Males	216	65.5
Females	114	34.5
Age groups
18–20 years	16	4.8
21–30 years	106	32.1
31–40 years	77	23.3
41–50 years	94	28.5
> 50 years	37	11.2
Total	330	100.0
Clinical history
No clinical history	274	83.0
Diabetes mellitus	8	2.4
Hypertension	18	5.5
Diabetes and hypertension	8	2.4
Prior SARS-COVID-19	8	2.4
Immune disease	2	0.6
Hypothyroidism	1	0.3
Hypertension and CVD	1	0.3
Diabetes mellitus and immune disease	2	0.6
Cardiovascular diseases	1	0.3
History of anaphylaxis	2	0.6
Thyroidectomy	1	0.3
CVD with diabetes mellitus and hypertension	1	0.3
Asthma	2	0.6
Depression	1	0.3
Total	330	17.0

Table 2 Post-Vaccination Symptoms of First and Second Doses of COVID-19 Vaccines

Symptoms	Frequency (%)
Fever	136 (41.2)
Muscle and joint pain	76 (23)
Redness at the injection site	4 (1.2)
Myalgia	121 (36.71)
Malaise	121 (36.71)
Fatigue	119 (36.1)
Pain and swelling at the injection site	65 (19.7)
Chills	46 (13.9)
Headache	86 (24.2)
Diarrhea	20 (6.1)
Depression	13 (3.9)
Muscle tone	16 (4.9)
Dizziness	27 (8.2)
Cough	11 (3.3)
Nausea	24 (7.3)
Seizures	3 (0.9)
Anxiety	7 (2.1)
Dyspnea	11 (3.3)
Swollen lip and tongue	3 (0.9)
Sore throat	24 (7.3)
Anosmia	4 (1.2)

Figure 1 Frequency of post-vaccination symptoms.

Table 3 The Onset of Symptoms in the First Dose and Second Dose of COVID-19 Vaccines

Onset of Symptoms	First Dose Frequency (%)	Second Dose Frequency (%)	χ^2	P-value
No symptoms after the first dose/second dose	106 (32.1)	70 (21.2)	156.610	< 0.001
< 5 minutes	10 (3.0)	14 (4.2)
6–10 minutes	9 (2.4)	3 (0.9)
11–15 minutes	4 (1.2)	5 (1.5)
> 15 minutes	83 (25.2)	32 (9.7)
<24 hours	85 (25.8)	1 (0.3)
< 24 hours	5 (1.5)	204 (61.8)
> 24 hours	28 (8.5)	1 (0.3)
Total	330	330

Table 4 The Onset of Adverse Events of Side Effects in the Two Common Types of COVID-19 Vaccines

Type of Vaccines	Post-Vaccination Symptoms		Total	χ^2	P-value
	Yes	No
Pfizer/BioNTech	102 (62.6%)	61 (37.4%)	163 (100.0%)	5.209	0.022
Oxford-AstraZeneca	124 (74.3%)	43 (25.7%)	167 (100.0%)
Total	226 (68.5%)	104 (31.5%)	330 (100.0%)

Figure 2 Percentage of participants who got infection with covid-19 after vaccination.

Figure 3 Comparison of post-vaccination side effects of first and second doses between males and females.

Table 5 The Most Common Adverse Events of Side Effects for Pfizer and Oxford-AstraZeneca Vaccines

Side Effects	Pfizer	Oxford-AstraZeneca	P-value
Myalgia	58 (47.9%)	63 (52.1%)	0.69
Malaise	47 (38.8%)	74 (61.2%)	0.004
Fever	46 (33.8%)	90 (66.2%)	> 0.001
Fatigue	46 (38.7%)	73 (61.3%)	0.003
Muscle and joint pain	27 (35.5%)	49 (64.5%)	0.006
Headache	21 (26.3%)	59 (73.8%)	< 0.001